Stopping hair loss isn't good enough to bring it to market; there is already a very effective protocol that stops hair loss in four out of five men, and it costs .15$/pill. And no, being "side effect-free" (and it WILL have side effects, because everything has side effects) won't differentiate Replicel - as it is, a significant portion of the marketplace doesn't care enough about hair loss to treat it, and of those that do, only a small percentage don't because of side-effect fears, and of those that don't because of side-effect fears, only a small percentage will pay / can pay 1000x the cost of a script for finasteride just to avoid the 2% chance of experiencing side effects. So you're talking about a sliver of a sliver of a market.
It will have to achieve 10%< regrowth to come to market, and substantially more than that. That is the operative metric, because equal to / less has been in the marketplace for the last fifteen years. I suspect that is why Replicel is conducting this study - they know that if they can't deliver consistent regrowth, they're dead in the water. Sorry, but this isn't positive news, and I don't know how anyone would characterize it as such.
As a side note, by the time hair loss is noticeable to the eye, you've already lost 50% of your hair, so even if something could completely halt any further loss, you're still down 50-75k hairs. So unless something can ALSO grow hair, it's not a "cure."
The side effects of this therapy are guaranteed to be far less severe than what can happen in unfortunate cases of finasteride.
In his most recent interview, Lee Buckler himself talked about the disadvantage of finasteride being the side effects, so to say that a side-effect free treatment is irrelevant in it coming to market when finasteride is recently discovered as potentially causing
fibrosis of the c***, and the company themselves being aware of side effects as a deterrent for treatment, is a moronic claim at best.
Which part? The part where Replicel decided the results were so poor they needed to commission a parallel study to figure out why?
Again, the data is out there - most men don't care enough about hair loss to do anything about it. Not because of side effects. Not because current protocols are too "inconvenient" - they just don't care enough to do anything, because there's nothing currently available that regrows a significant amount of hair. And as for your birth control comparison, if an IUD cost $10,000, do you think they'd be a competitive option with the Pill? Because for the percentage of men who DO care about hair loss and aren't worried about nearly non-existent side effects, that's the choice they'll be faced with - a .15$ pill or a $10,000+ series of injections. And as for female hair loss, sorry, but from a Pharma perspective, no one cares - there just isn't that big of a market to treat it. There's a reason every single one of the current and recruiting trials use men exclusively.
I'm not saying Replicel is finished - far from it. But they are obviously seeing something they don't like; when is it ever a good sign when a company commissions a secondary study of an ongoing trial?
Regardless, Follica works, and it's definitely getting to market many, many years before Replicel does (if Replicel ever does).
There is not a person alive who, if the option of getting a one-time injection to permanently stop hairloss, would not take it. You know this too, since all your "fears" a few months back that other treatments might not be developed if a "vaccine" for hairloss exists? Now that you're worried about losing that precious $, the only reason you follow this stuff at all, you've changed your opinion...again.
You are
actually complaining about a company investigating how to best optimize results. Also, you may want to check that study again because most patients DID see results comparable or better to conventional treatment; there was only one with exceptionally good results, however.
Shiseido still seems fully intent on bringing it to market and RepliCel still plans to go on with Phase II regardless. So your gloom and doom is unwarranted.
A company tries to figure out why some people had better regrowth than others with the aim of giving every patient high regrowth and they're "poor results", but Follica
totally works like a charm because dermarolling
can work and you
know their procedure is great based on that alone, despite no data on it being available to the public yet.
Your own logical inconsistencies and backtracking whenever you're worried your money is in danger are truly hilarious.
The only real question here is — how much money do you have invested in PureTech?